首页|HIV感染急性期治疗对α4β7肠道归巢CD4细胞保护作用的研究

HIV感染急性期治疗对α4β7肠道归巢CD4细胞保护作用的研究

Protection for gut-homing α4β7 CD4 cells from acute HIV infection treatment

扫码查看
原文链接
  • 维普
  • 万方数据
目的 探讨HIV感染急性期ART对α4β7肠道归巢CD4细胞及其功能亚群的保护作用.方法 入组HIV感染急性期(AHI)cART患者71名、慢性期(CHI)cART患者29名和HIV抗体阴性健康对照者(HC)32名.采用流式分析方法,分别检测HC、AHI和CHI在cART基线(0周)、24周、48周和96周α4β7CD4细胞及其功能亚群α4β7Treg、α4β7Th1 和α4β7Th17比例;HC、AHI 和CHI 0周和96周CD38+HLA-DR+CD8细胞比例.ELISA检测 HC、AHI和CHI 0周和96周血浆可溶性CD14(sCD14)浓度.结果 与HC相比,AHI和CHI α4β7CD4细胞比例在0周均显著下降[AHI vs.HC:(8.214±3.074)vs.(10.027±2.617),P＜0.010;CHI vs.HC:(7.290±2.295)vs.(10.027±2.617),P＜0.010].cART96周后,AHI和CHI α4β7CD4细胞比例仍显著低于HC.AHI 0周和96周α4β7Th17细胞比例与HC差异无统计学意义.不同基线CD4细胞数量开展AHIcART过程中,α4β7Th17细胞比例差异均无统计学意义,且0周α4β7Th17细胞比例与0周和cART 96周血浆sCD14浓度(0周:r=-0.310,P=0.018;96周:r=-0.270,P=0.039)、0周CD38+HLA-DR+CD8细胞比例(r=-0.279,P=0.042)负相关.结论 开展急性期cART可以有效保护α4β7CD4细胞亚群α4β7Th17细胞.
Objective This study aims to investigate how antiretroviral therapy(cART)during acute HIV infection protects gut-homing α4β7CD4 cells and their subsets.Methods A total of 71 patients with acute HIV infection(AHI)and receiving ART,29 with chronic HIV infection(CHI)and receiving cART,and 32 healthy controls(HC)testing negative for HIV were enrolled in this study.Multicolor flow cytometry was used for the proportional analysis ofα4β7CD4 cells and their functional subsets α4β7Treg,α4β7Th1,and α4β7Th17 in HC,AHI,and CHI at cART baseline(0 week),24 week,48 week,and 96 week.The proportions of CD38+HLA-DR+CD8 cells in HC,AHI and CHI at 0 week and 96 week were also analyzed.ELISA was used to measure the concentration of plasma soluble CD14(sCD14)in HC,AHI and CHI at 0 week and 96 week.Results Compared with HC,the proportions of α4β7CD4 cells in AHI and CHI at 0 week significantly declined(AHI vs.HC:8.214±3.074 vs.10.027±2.617,P＜0.010;CHI vs.HC:7.290±2.295 vs.10.027± 2.617,P＜0.010),and lower than those in HC after 96 weeks of treatment.The percentage of α4β7Th17 in AHI exhibited no statistical difference from that in HC at 0 week and 96 week.Throughout the AHI cART process,there were no statistical differences among different CD4 cell baseline groups in the proportions of α4β7Th17.Further,the proportion of α4β7Th17 at 0 week was negatively correlated to the concentration of plasma sCD14 at 0 week(r=-0.310,P=0.018)and 96 week(r=-0.270,P=0.039)as well as that of CD38+HLA-DR+CD8 cells at 0 week(r=-0.279,P=0.042).Conclusions Providing cART during acute HIV infection effectively protects α4β7Th17 cells.

HIVtreatment for acute HIV infectiongut-homingα4β7Th17

王蕊、计云霞、陆小凡

展开 >

首都医科大学附属北京佑安医院感染性疾病临床研究中心艾滋病研究北京市重点实验室,北京 100069

艾滋病病毒 急性期治疗 肠道归巢 α4β7 Th17

北京市教育委员会科学研究计划项目北京市卫生健康委员会高层次公共卫生技术人才建设项目首都医科大学附属北京佑安医院中青年人才培养计划专项艾滋病研究北京市重点实验室High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission

KM202010025015学科骨干-02-21YARCKB2022002BZ00892023-02-21

2024

10.13419/j.cnki.aids.2024.01.01

中国艾滋病性病
中国性病艾滋病防治协会

中国艾滋病性病

CSTPCD北大核心
影响因子：1.292
ISSN：1672-5662
年,卷(期)：2024.30(1)
  • 1